Farnesyl transferase inhibitors cause enhanced mitotic sensitivity to taxol and epothilones
about
The protein farnesyltransferase regulates HDAC6 activity in a microtubule-dependent mannerRhoB alteration is necessary for apoptotic and antineoplastic responses to farnesyltransferase inhibitorsNew targets for therapy in breast cancer: farnesyltransferase inhibitors.Farnesyl transferase inhibitors block the farnesylation of CENP-E and CENP-F and alter the association of CENP-E with the microtubulesMicrotubule dysfunction induced by paclitaxel initiates apoptosis through both c-Jun N-terminal kinase (JNK)-dependent and -independent pathways in ovarian cancer cellsAnalysis of high-throughput RNAi screening data in identifying genes mediating sensitivity to chemotherapeutic drugs: statistical approaches and perspectivesCell cycle-related changes in regulatory volume decrease and volume-sensitive chloride conductance in mouse fibroblasts.Phase I and pharmacokinetic study of irinotecan in combination with R115777, a farnesyl protein transferase inhibitor.Measurement of protein farnesylation and geranylgeranylation in vitro, in cultured cells and in biopsies, and the effects of prenyl transferase inhibitorsTargeting protein prenylation for cancer therapyAnticancer drug targets: growth factors and growth factor signaling.Paclitaxel-induced cell death: where the cell cycle and apoptosis come together.Blocking oncogenic Ras signaling for cancer therapy.Treatment of advanced non-small-cell lung cancer: a review of current randomized clinical trials and an examination of emerging therapies.Farnesyltransferase inhibitors: mechanism and applications.The search for optimal treatment in relapsed and refractory acute myeloid leukemia.Lipid posttranslational modifications. Farnesyl transferase inhibitors.Farnesyl transferase expression determines clinical response to the docetaxel-lonafarnib combination in patients with advanced malignancies.Emerging drugs for non-small cell lung cancer.Preventing farnesylation of the dynein adaptor Spindly contributes to the mitotic defects caused by farnesyltransferase inhibitors.Farnesyltransferase inhibitors reverse taxane resistanceThe synergistic combination of the farnesyl transferase inhibitor lonafarnib and paclitaxel enhances tubulin acetylation and requires a functional tubulin deacetylase.Novel targeted agents in the treatment of lung cancer.Anatomy of a joint venture: Dana Farber/Partners Cancer Care.The antibody catalysis route to the total synthesis of epothilones.Inhibition of farnesyltransferase: a rational approach to treat cancer?Farnesyltransferase inhibitors induce dramatic morphological changes of KNRK cells that are blocked by microtubule interfering agents.Mechanisms of Chromosome Congression during Mitosis.Effects of zoledronic acid and docetaxel on small GTP-binding proteins in prostate cancer.Modulation of anthracycline-induced cytotoxicity by targeting the prenylated proteome in myeloid leukemia cells.Working together: Farnesyl transferase inhibitors and statins block protein prenylation.The farnesyl transferase inhibitor (FTI) SCH66336 (lonafarnib) inhibits Rheb farnesylation and mTOR signaling. Role in FTI enhancement of taxane and tamoxifen anti-tumor activity.Farnesyltransferase inhibitor R115777 (Zarnestra, Tipifarnib) synergizes with paclitaxel to induce apoptosis and mitotic arrest and to inhibit tumor growth of multiple myeloma cells.Cdk inhibitors, roscovitine and olomoucine, synergize with farnesyltransferase inhibitor (FTI) to induce efficient apoptosis of human cancer cell lines.Association between mitotic spindle checkpoint impairment and susceptibility to the induction of apoptosis by anti-microtubule agents in human lung cancers.H-ras localizes to cell nuclei and varies with the cell cycleK-Ras-independent effects of the farnesyl transferase inhibitor L-744,832 on cyclin B1/Cdc2 kinase activity, G2/M cell cycle progression and apoptosis in human pancreatic ductal adenocarcinoma cellsInhibition of human tumor cell growth in vivo by an orally bioavailable inhibitor of human farnesyltransferase, BIM-46228.In vivo metabolism of epothilone B in tumor-bearing nude mice: identification of three new epothilone B metabolites by capillary high-pressure liquid chromatography/mass spectrometry/tandem mass spectrometry.RPR-115135, a farnesyltransferase inhibitor, increases 5-FU- cytotoxicity in ten human colon cancer cell lines: role of p53.
P2860
Q24312194-F343509B-6CC7-43A2-9071-1BE4AD642A58Q24552386-53CAEF3D-A7AF-4F41-8FBA-DE59D8838CB6Q24796277-87D74486-2B99-4E65-9248-AF9B9A4D5E73Q28138265-D6EB6D3C-F5D5-46E7-A768-0615DA66014CQ28371622-17C3F9FC-B25D-42C0-BE5A-CEA3844BA1F3Q30583965-6654FC96-35FD-4B17-951F-746553E14655Q32160539-07F0A307-9E89-4241-925A-627B22F768B4Q33201555-79D0D7A2-CECF-4E30-812B-F69160BA5045Q33669995-752285E6-68FC-4390-841A-672D5BAF4440Q33679239-C24D0FEA-27BD-4627-A23F-06FC1C4DACC9Q33808352-7B09C6EA-E133-49E1-8EAB-906018027BE5Q33947088-DF1D5022-0774-46FF-B8E0-86691ED45376Q34311585-147F8B64-AF33-4E5C-828D-C679CD0C2070Q34325219-E3485E8B-17BF-4C10-B18C-DDD5E47614B9Q34481874-479C5C80-54D2-41E9-BC5F-4125D1E4A6A8Q34630777-C9ADAF99-1297-41F3-AA9D-8D2E27603F3FQ34651253-8FD7CFB3-0B66-48B0-96E8-41BC242B9D3FQ35091519-31601F74-437E-49CC-8B34-08C75C7339D5Q35581167-CFE3D3ED-D1A3-45CE-A00B-06E99D744BC1Q35621957-7556890E-11B0-43E7-86F0-133BBFF6DFF1Q35774556-11C12B96-4C34-4E25-BBA2-3069D907B81EQ35774565-DD1ECC07-615E-468D-8328-D780C51532CDQ35790783-85D00F63-44FF-4286-953D-5AE767FADE5FQ36371988-282D6A4C-3E0C-4539-8273-19FC053056AEQ36752669-44D27F39-EBC9-43CA-B050-4E20A824A4F0Q36828655-CE70B00A-B1FE-4685-9389-E04E629EF173Q37472121-5B1F494B-8823-4AB3-8C9C-C67F33B778DBQ37728193-FC53F591-01D3-4934-B009-24F9C1EAEA81Q38915441-C1339F74-B451-4076-8043-F798191F1B5FQ39474160-A13F74C3-8761-4762-A409-1710AACEC20BQ40149906-E3AE6C88-06F6-463A-B71B-400B1BE1911CQ40399733-9D762C6E-3A24-4335-B655-DF0BC74CDEAFQ40455268-5A2EFC34-4A9F-4A61-B03F-DF5373F1CB59Q40871201-A736E9FB-2F73-4BE6-AFF7-8FBCEFE2307AQ41824137-9D51D063-20FB-4034-A641-3589479877C6Q42210981-FF289FB9-1269-4CC8-9F5D-E94F402EA8A0Q42357855-C98E41D0-1E73-4D72-BB62-383AF05C12FDQ42830828-EF7BB653-0E19-4D11-84BF-35734F0BDBD3Q43514585-1C5B68B9-1702-4C17-824D-B8AC1A67E490Q44062538-38310562-A9BC-48FC-B6AA-0CEBB43EAC7D
P2860
Farnesyl transferase inhibitors cause enhanced mitotic sensitivity to taxol and epothilones
description
1998 nî lūn-bûn
@nan
1998年の論文
@ja
1998年論文
@yue
1998年論文
@zh-hant
1998年論文
@zh-hk
1998年論文
@zh-mo
1998年論文
@zh-tw
1998年论文
@wuu
1998年论文
@zh
1998年论文
@zh-cn
name
Farnesyl transferase inhibitor ...... ivity to taxol and epothilones
@ast
Farnesyl transferase inhibitor ...... ivity to taxol and epothilones
@en
type
label
Farnesyl transferase inhibitor ...... ivity to taxol and epothilones
@ast
Farnesyl transferase inhibitor ...... ivity to taxol and epothilones
@en
prefLabel
Farnesyl transferase inhibitor ...... ivity to taxol and epothilones
@ast
Farnesyl transferase inhibitor ...... ivity to taxol and epothilones
@en
P2093
P2860
P356
P1476
Farnesyl transferase inhibitor ...... ivity to taxol and epothilones
@en
P2093
L Sepp-Lorenzino
M M Moasser
S J Danishefsky
P2860
P304
P356
10.1073/PNAS.95.4.1369
P407
P577
1998-02-01T00:00:00Z